middle.news
Anatara Lifesciences Secures Australian Patent for GaRP Ahead of Key IBS Trial Results
7:03pm on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Anatara Lifesciences Secures Australian Patent for GaRP Ahead of Key IBS Trial Results
7:03pm on Monday 2nd of June, 2025 AEST
Key Points
Australian patent granted for GaRP valid until 2040
European patent secured in September 2024, with ongoing global patent prosecution
GaRP-IBS Phase II trial headline results anticipated in Q1 2025
GaRP targets a significant US$8 billion non-prescription gastrointestinal market
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anatara Lifesciences (ASX:ANR)
OPEN ARTICLE